Sell4

HALOZYME THERAPEUTICS, INC.

HALO

Total Value

$8.5M

Net $6.3M sold

Filing Date

Aug 19, 2026

11 transactions

Sales

$6.3M

11 transactions

Trade Summary

On Aug 17, 2026 through Aug 19, 2026, Torley Helen, PRESIDENT AND CEO, Director, sold $8.5M of HALOZYME THERAPEUTICS, INC. (HALO) across 11 transactions. The filing covers Common Stock and reflects net selling of $6.3M. Reported prices ranged from $18.41 to $107.77. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

HALO daily price with the insider's sale marked at $104.59.

Sold near the 6-month high · the stock trades 2% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Torley Helen
Role: PRESIDENT AND CEO, Director
Location: SAN DIEGO, CA

Filing Details

Filing Date: Aug 19, 2026
Transaction Date: Aug 17, 2026
Accession Number: 0001159036-26-000108
Form Type: 4
Net Trading Amount: -$6.3M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 17, 2026	Common Stock	20,000	$18.41	Exercise	$368.2K
Aug 17, 2026	Common Stock	900	$98.96	Sale	$89.1K
Aug 17, 2026	Common Stock	500	$100.46	Sale	$50.2K
Aug 17, 2026	Common Stock	2,100	$101.77	Sale	$213.7K
Aug 17, 2026	Common Stock	9,000	$102.55	Sale	$923.0K
Aug 17, 2026	Common Stock	7,500	$103.48	Sale	$776.1K
Aug 18, 2026	Common Stock	20,000	$18.41	Exercise	$368.2K
Aug 18, 2026	Common Stock	5,703	$103.08	Sale	$587.9K
Aug 18, 2026	Common Stock	4,897	$104.11	Sale	$509.8K
Aug 18, 2026	Common Stock	9,400	$104.87	Sale	$985.8K
Aug 19, 2026	Common Stock	20,000	$18.41	Exercise	$368.2K
Aug 19, 2026	Common Stock	7,200	$106.36	Sale	$765.8K
Aug 19, 2026	Common Stock	9,600	$107.22	Sale	$1.0M
Aug 19, 2026	Common Stock	3,200	$107.77	Sale	$344.8K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 17, 2026	HALO derivative	20,000	$18.41	Exercise	$368.2K
Aug 18, 2026	HALO derivative	20,000	$18.41	Exercise	$368.2K
Aug 19, 2026	HALO derivative	20,000	$18.41	Exercise	$368.2K

Want live alerts when Torley Helen trades again?

Download Insider Trades to track HALO, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
(F2)Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F3)Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F4)Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F5)Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F6)Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F7)Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F8)Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F9)Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F10)Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F11)Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F12)Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
(F13)Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		M⁽¹⁾		20,000	A	$18.41	787,780	D
Common Stock	08/17/2026		S⁽¹⁾		900	D	$98.958⁽²⁾	786,880	D
Common Stock	08/17/2026		S⁽¹⁾		500	D	$100.457⁽³⁾	786,380	D
Common Stock	08/17/2026		S⁽¹⁾		2,100	D	$101.766⁽⁴⁾	784,280	D
Common Stock	08/17/2026		S⁽¹⁾		9,000	D	$102.553⁽⁵⁾	775,280	D
Common Stock	08/17/2026		S⁽¹⁾		7,500	D	$103.482⁽⁶⁾	767,780	D
Common Stock	08/18/2026		M⁽¹⁾		20,000	A	$18.41	787,780	D
Common Stock	08/18/2026		S⁽¹⁾		5,703	D	$103.083⁽⁷⁾	782,077	D
Common Stock	08/18/2026		S⁽¹⁾		4,897	D	$104.11⁽⁸⁾	777,180	D
Common Stock	08/18/2026		S⁽¹⁾		9,400	D	$104.874⁽⁹⁾	767,780	D
Common Stock	08/19/2026		M⁽¹⁾		20,000	A	$18.41	787,780	D
Common Stock	08/19/2026		S⁽¹⁾		7,200	D	$106.358⁽¹⁰⁾	780,580	D
Common Stock	08/19/2026		S⁽¹⁾		9,600	D	$107.224⁽¹¹⁾	770,980	D
Common Stock	08/19/2026		S⁽¹⁾		3,200	D	$107.765⁽¹²⁾	767,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$18.41	08/17/2026		M⁽¹⁾			20,000	⁽¹³⁾	02/14/2028	Common Stock	20,000	$18.41	181,552	D
Option to Purchase Common Stock	$18.41	08/18/2026		M⁽¹⁾			20,000	⁽¹³⁾	02/14/2028	Common Stock	20,000	$18.41	161,552	D
Option to Purchase Common Stock	$18.41	08/19/2026		M⁽¹⁾			20,000	⁽¹³⁾	02/14/2028	Common Stock	20,000	$18.41	141,552	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

11. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

12. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

13. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001159036-26-000108.

HALOZYME THERAPEUTICS, INC.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Torley Helen trades again?

Footnotes

SEC Form 4

SEC Filing

Price at the Time of the Trade

SEC Form 4